Concord Biotech IPO subscribed 58% on first day
The Initial Public Offering (IPO) got bids for 85,05,660 shares against 1,46,50,957 on offer, according to the National Stock Exchange (NSE) data.
Concord is among leading manufacturers of fermentation-based biopharmaceutical active pharmaceutical ingredient (API), focused on niche segments such as immunosuppressant, oncology, anti-fungal and anti-bacterial.( Image credit : Official website)